inclusion criteria: 1. aged ≥ 18 and ≤65 years old. 2. laboratory confirmed sars-cov-2 infection, with first positive pcr test results within the past 48 hours of randomization. 3. participants with covid-19 symptoms within 5 days prior to the day of randomization, based on the following criteria: at least two of the following symptoms: stuffy/runny nose, sore throat, shortness of breath, cough, low energy/tiredness, muscle/body aches, headache, chill/shivering, fever (≥ 38ºc), nausea, vomiting, diarrhea, and loss of taste or smell. 4. have a mild or moderate form of covid-19 defined as: respiratory rate ≤30 breaths per minute, heart rate ≤125 beats per minute; with saturation of oxygen (spo2) ≥93% on room air at sea level no clinical signs listed in inclusion criteria #3 indicative of severe severity 5. have a negative pregnancy test at screening (for female participants of childbearing potential). 6. participant or the participant's legal representative understands the study procedures, alternative treatments available, risks involved with the study, and voluntarily agrees to participate by giving written informed consent. 7. provide written informed consent for the study and willing to adhere to dose regimen and visit schedules.

inclusion criteria: 1. aged ≥ 18 and ≤65 years old. 2. laboratory confirmed sars-cov-2 infection, with first positive pcr test results within the past 48 hours of randomization. 3. participants with covid-19 symptoms within 5 days prior to the day of randomization, based on the following criteria: at least two of the following symptoms: stuffy/runny nose, sore throat, shortness of breath, cough, low energy/tiredness, muscle/body aches, headache, chill/shivering, fever (≥ 38ºc), nausea, vomiting, diarrhea, and loss of taste or smell. 4. have a mild or moderate form of covid-19 defined as: respiratory rate ≤30 breaths per minute, heart rate ≤125 beats per minute; with saturation of oxygen (spo2) ≥93% on room air at sea level no clinical signs listed in inclusion criteria #3 indicative of severe severity 5. have a negative pregnancy test at screening (for female participants of childbearing potential). 6. participant or the participant's legal representative understands the study procedures, alternative treatments available, risks involved with the study, and voluntarily agrees to participate by giving written informed consent. 7. provide written informed consent for the study and willing to adhere to dose regimen and visit schedules.

inclusion criteria: aged ≥ 18 and ≤65 years old. laboratory confirmed sars-cov-2 infection, with first positive pcr test results within the past 48 hours of randomization. participants with covid-19 symptoms within 5 days prior to the day of randomization, based on the following criteria: at least two of the following symptoms: stuffy/runny nose, sore throat, shortness of breath, cough, low energy/tiredness, muscle/body aches, headache, chill/shivering, fever (≥ 38ºc), nausea, vomiting, diarrhea, and loss of taste or smell. have a mild or moderate form of covid-19 defined as: respiratory rate ≤30 breaths per minute, heart rate ≤125 beats per minute; with saturation of oxygen (spo2) ≥93% on room air at sea level no clinical signs listed in inclusion criteria #3 indicative of severe severity have a negative pregnancy test at screening (for female participants of childbearing potential). participant or the participant's legal representative understands the study procedures, alternative treatments available, risks involved with the study, and voluntarily agrees to participate by giving written informed consent. provide written informed consent for the study and willing to adhere to dose regimen and visit schedules.

inclusion criteria: aged ≥ 18 and ≤65 years old. laboratory confirmed sars-cov-2 infection, with first positive pcr test results within the past 48 hours of randomization. participants with covid-19 symptoms within 5 days prior to the day of randomization, based on the following criteria: at least two of the following symptoms: stuffy/runny nose, sore throat, shortness of breath, cough, low energy/tiredness, muscle/body aches, headache, chill/shivering, fever (≥ 38ºc), nausea, vomiting, diarrhea, and loss of taste or smell. have a mild or moderate form of covid-19 defined as: respiratory rate ≤30 breaths per minute, heart rate ≤125 beats per minute; with saturation of oxygen (spo2) ≥93% on room air at sea level no clinical signs listed in inclusion criteria #3 indicative of severe severity have a negative pregnancy test at screening (for female participants of childbearing potential). participant or the participant's legal representative understands the study procedures, alternative treatments available, risks involved with the study, and voluntarily agrees to participate by giving written informed consent. provide written informed consent for the study and willing to adhere to dose regimen and visit schedules.